De novo fatty acid synthesis-driven sphingolipid metabolism promotes metastatic potential of colorectal cancer

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Abstract

Metastasis is the most common cause of death in colorectal cancer patients. Fatty acid synthase (FASN) and sphingosine kinase-1 and -2 (SPHK1 and 2) are overexpressed in many cancers, including colorectal cancer. However, the contribution of FASN-mediated upregulation of sphingolipid metabolism to colorectal cancer metastasis and the potential of these pathways as targets for therapeutic intervention remain unknown. This study determined that sphingosine kinases (SPHK) are overexpressed in colorectal cancer as compared with normal mucosa. FASN expression significantly correlated with SPHK2 expression in data sets from The Cancer Genome Atlas (TCGA) and a colorectal cancer tumor microarray. FASN, SPHK1, and SPHK2 colocalized within invadopodia of primary colorectal cancer cells. Moreover, FASN inhibition decreased SPHK2 expression and the levels of dihydrosphingosine 1-phosphate (DH-S1P) and sphingosine 1-phosphate (S1P) in colorectal cancer cells and tumor tissues. Inhibition of FASN using TVB-3664 and sphingolipid metabolism using FTY-720 significantly inhibited the ability of primary colorectal cancer cells to proliferate, migrate, form focal adhesions, and degrade gelatin. Inhibition of the FASN/SPHK/S1P axis was accompanied by decreased activation of p-MET, p-FAK, and p-PAX. S1P treatment rescued FASN-mediated inhibition of these proteins, suggesting that FASN promotes metastatic properties of colorectal cancer cells, in part, through an increased sphingolipid metabolism. These data demonstrate that upregulation of the FASN/SPHK/S1P axis promotes colorectal cancer progression by enhancing proliferation, adhesion, and migration. Implications: This study provides a strong rationale for further investigation of the interconnection of de novo lipogenesis and sphingolipid metabolism that could potentially lead to the identification of new therapeutic targets and strategies for colorectal cancer.

Original languageEnglish
Pages (from-to)140-152
Number of pages13
JournalMolecular Cancer Research
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2019

Bibliographical note

Publisher Copyright:
2018 American Association for Cancer Research.

Funding

The University of Kentucky Markey Cancer Center's Research Communications Office and Donna Gilbreath assisted in preparation of this article. The authors thank the Biospecimen and Tissue Procurement Shared Resource Facility (SRF), Redox Metabolism SRF, and Biostatistics and Bioinformatics SRF of the University of Kentucky Markey Cancer Center (supported by NCI grant P30 CA177558). This work is supported by grants from 3-V Biosciences, Inc. (Y.Y. Zaytseva); ACS IRG 85-001-25 (Y.Y. Zaytseva); and NCI K22 CA197193 (Y.Y. Zaytseva), P20 GM121327 (Y.Y. Zaytseva), R01 CA133429 (T. Gao), and R01 CA208343 (B.M. Evers and T. Gao).

FundersFunder number
3-V Biosciences, Inc.
Redox Metabolism SRF
National Childhood Cancer Registry – National Cancer InstituteP30 CA177558, K22 CA197193, R01 CA133429, R01 CA208343
National Institute of General Medical Sciences DP2GM119177 Sophie Dumont National Institute of General Medical SciencesP20GM121327
American Chemical SocietyIRG 85-001-25
American Chemical Society Petroleum Research Fund85-001-25
National Computational Infrastructure
Horizon 2020 Framework ProgrammeGM121327
University of Kentucky Markey Comprehensive Cancer Center

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    ASJC Scopus subject areas

    • Molecular Biology
    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'De novo fatty acid synthesis-driven sphingolipid metabolism promotes metastatic potential of colorectal cancer'. Together they form a unique fingerprint.

    Cite this